Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or... – Recovery or purification
Reexamination Certificate
2008-07-14
2010-11-16
Mosher, Mary E (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
Recovery or purification
C435S235100, C435S325000, C435S350000, C435S365000, C435S367000, C435S369000, C435S372000, C435S354000, C424S209100
Reexamination Certificate
active
07833774
ABSTRACT:
The present invention relates, in general, to a screening method for identifying novel viral proteins with interferon antagonizing function using a transfection-based assay, and the use of such proteins in isolating various types of attenuated viruses for the development of vaccine and pharmaceutical formulations. The invention also relates to the use of viral interferon antagonists in screening assays to identify potential anti-viral agents. The invention further relates to protocols utilizing interferon antagonists, e.g., NS1, to enhance gene therapy or DNA vaccination based on their ability to increase gene expression.
REFERENCES:
patent: 4071618 (1978-01-01), Konobe et al.
patent: 4567147 (1986-01-01), Ooi et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 5166057 (1992-11-01), Palese et al.
patent: 5674502 (1997-10-01), Ennis et al.
patent: 5766601 (1998-06-01), Ennis
patent: 5786199 (1998-07-01), Palese et al.
patent: 5820871 (1998-10-01), Palese et al.
patent: 5854037 (1998-12-01), Palese et al.
patent: 5866694 (1999-02-01), Katinger et al.
patent: 5882650 (1999-03-01), Ennis
patent: 6146642 (2000-11-01), Garcia-Sastre et al.
patent: 6146873 (2000-11-01), Kistner et al.
patent: 6300090 (2001-10-01), Steinman et al.
patent: 6326151 (2001-12-01), Katze et al.
patent: 6468544 (2002-10-01), Egorov et al.
patent: 6544785 (2003-04-01), Palese et al.
patent: 6573079 (2003-06-01), Palese et al.
patent: 6635416 (2003-10-01), Palese et al.
patent: 6669943 (2003-12-01), Palese et al.
patent: 6673591 (2004-01-01), Lau
patent: 6686190 (2004-02-01), Lau
patent: 6800288 (2004-10-01), Ferko et al.
patent: 6852522 (2005-02-01), Palese et al.
patent: 6866853 (2005-03-01), Egorov et al.
patent: 6884414 (2005-04-01), Palese et al.
patent: 7060430 (2006-06-01), Palese et al.
patent: 7132271 (2006-11-01), Lau
patent: 7344722 (2008-03-01), Maassab et al.
patent: 7442527 (2008-10-01), Palese et al.
patent: 7494659 (2009-02-01), Katinger et al.
patent: 7494808 (2009-02-01), Palese et al.
patent: 7588768 (2009-09-01), Palese et al.
patent: 2004/0109877 (2004-06-01), Palese et al.
patent: 2004/0137013 (2004-07-01), Katinger et al.
patent: 2004/0253273 (2004-12-01), Palese et al.
patent: 2005/0054074 (2005-03-01), Palese et al.
patent: 2007/0122430 (2007-05-01), Shneider et al.
patent: 2007/0172929 (2007-07-01), Maassab et al.
patent: 2008/0050402 (2008-02-01), Zhou et al.
patent: 2008/0234175 (2008-09-01), Montelione et al.
patent: 2008/0254060 (2008-10-01), Palese et al.
patent: 2009/0010962 (2009-01-01), Palese et al.
patent: 2009/0053264 (2009-02-01), Palese et al.
patent: 2009/0203114 (2009-08-01), Palese et al.
patent: 100 20 505 (2001-10-01), None
patent: 702085 (1996-03-01), None
patent: 780475 (1997-06-01), None
patent: 780475 (1997-06-01), None
patent: 1085904 (1999-12-01), None
patent: 1098961 (2008-01-01), None
patent: 59-39831 (1984-03-01), None
patent: WO 96/10632 (1996-04-01), None
patent: WO 96/34625 (1996-11-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/08292 (1997-03-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/13501 (1998-04-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15672 (1999-04-01), None
patent: WO 99/64068 (1999-12-01), None
patent: WO 99/64570 (1999-12-01), None
patent: WO 99/64571 (1999-12-01), None
patent: WO 01/64860 (2001-09-01), None
patent: WO 01/77394 (2001-10-01), None
patent: WO 02/24876 (2002-03-01), None
patent: WO 2006/083286 (2006-08-01), None
patent: WO 2006/088481 (2006-08-01), None
Hjelle. “Vaccines against hantaviruses.” Expert Reviews of Vaccines 1:373-384, 2002.
Hevey et al. “Marburg virus vaccines: comparing classical and new approaches.” Vaccine 20 (2002) 586-593.
Weber et al. “Inverse Interference: How Viruses Fight the Interferon System.” Viral Immunology 17: 498-525, 2004.
Garcia-Sastre. “Inhibition of Interferon-Mediated Antiviral Responses by Influenza A Viruses and Other Negative-Strand RNA Viruses.” Virology 279, 375-384 (2001).
Hengel et al. “Viruses know it all: new insights into IFN networks.” TRENDS in Immunology 26: 397-401, 2005.
Murphy, F. A. “Virus Taxonomy.” in Fields Virology, Third edition, ed. B. N. Fields et al, Lippencott-Raven Publishers, Philadelphia, PA, 1996; pp. 15-57.
Baskin et al., Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J Virol. Nov. 2007;81(21):11817-27.
Basler et al., The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A. Oct. 24, 2000;97(22):12289-94.
Beattie et al., 1995, “Reversal of the Interferon-Sensitive Phenotype of a Vaccinia Virus Lacking E3L by Expression of the Reovirus S4 Gene,” J. Virology 69(1):499-505.
Bergmann et al., Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J Virol. Jul. 2000;74(13):6203-6.
Bossert et al., 2002, “Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV Is Attenuated in Interferon-Competent Bovine Cells”, J. of Virology 76:4287-93.
Butterfield and Campbell, 1978, “Vaccination for Fowl Plague”, Selected Reports and Notes, 671-674.
Chang et al., “The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase.”, Proc Natl Acad Sci U S A. Jun. 1, 1992;89(11):4825-9.
Chen Z et al., “Influenza A virus NS1 protein targets poly(A)-binding protein II of the cellular 3′-end processing machinery”, EMBO J. Apr. 15, 1999:18(8):2273-83.
Clemens and Elia, 1997, “The Double Stranded RNA-Dependent Protein Kinase PKR: Structure and Function”, Journal of Interferon and Cytokine Research, 17:503-524.
De La Luna S et al., “Influenza virus NS1 protein enhances the rate of translation initiation of viral mRNAs”, J Virol. Apr. 1995;69(4):2427-33.
Desmyter J et al., “Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)”, J Virol. Oct. 1968;2(10):955-61.
Didcock et al., 1999, “The V Protein of Simian Virus 5 Inhibits Interferon Signalling by Targeting STAT1 for Proteasome-Mediated Degradation”, J. of Virology, 73(12): 9928-9933.
Donelan et al., The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation. J Virol. Nov. 2004;78(21):11574-82.
Donelan et al., A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol. Dec. 2003;77(24):13257-66.
Egorov A et al., “The NS gene—a possible determinant of apathogenicity of a cold-adapted donor of attenuation A /Leningrad/134/47/57 and its reassortants”, Vopr Virusol. Sep.-Oct. 1994;39(5):201-5. Russian.
Egorov A et al., “Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells”, J Virol. Aug. 1998:72(8):6437-41.
Egorov AY et al., “Generation of influenza A transfectant viruses containing deletions of the carboxyl-terminal part of the NS1 protein”, in Emergence and Re-emergence of Negative Strand Viruses, Tenth International Conference on Negative Strand Viruses. Sep. 21-26, 1997, Dublin, Ireland. Abstract No. 108, p. 104.
Enami K et al., “Influenza virus NS1 protein stimulates translation of the M1 protein”, J Virol. Mar. 1994;68(3):1432-7.
Enami M and Palese P, “High-efficiency formation of influenza virus transfectants”, J Virol. May 1991;65(5):2711-3.
Enami M et al., “An influenza virus containing nine different RNA segments”, Virology. Nov. 1991;185(1):291-8.
Falcon et al., Attenuation and immunogenici
Basler Christopher
Garcia-Sastre Adolfo
Palese Peter M.
Jones Day
Mosher Mary E
Mount Sinai School of Medicine of New York University
LandOfFree
Screening methods for identifying viral proteins with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening methods for identifying viral proteins with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening methods for identifying viral proteins with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4235964